A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibodyas Monotherapy and in Combination with AGEN2034 (balstilimab), an Anti-PD-1Monoclonal Antibody, in Subjects with Advanced Cancer
Study of AGEN1181 Alone or in Combination with Balstilimab in Patients with Advanced Sarcoma
Sponsor: Agenus Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU0656
U.S. Govt. ID: NCT03860272
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study mainly aims to test the safety and tolerability of AGEN1181 and balstilimab and to determine the most appropriate dose of the study drug AGEN1181 alone and in combination with balstilimab. AGEN1181 targets cells that are a part of the body's immune system to block a protein called cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). Balstilimab can specially block a protein called programmed-death 1 (PD-1) and prevent communication between this protein and receptors on the tumor cells. These receptors are known to affect the body's defense mechanism to identify and fight against cancerous cells. Blocking these proteins is believed to improve the ability of your immune system to fight your cancer. The study drugs are investigational meaning that a regulatory authority, such as the U.S. Food and Drug Administration (FDA), has not approved the study drugs for use in people.
Investigator
Gary Schwartz, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with a advanced sarcoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162